Athersys (FRA:4LSA) Asset Impairment Charge : €0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Athersys Asset Impairment Charge?

Athersys's Asset Impairment Charge for the three months ended in Sep. 2023 was €0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2023 was €0.00 Mil.

Athersys Asset Impairment Charge Historical Data

The historical data trend for Athersys's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athersys Asset Impairment Charge Chart

Athersys Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Asset Impairment Charge

Get a 7-Day Free Trial

6.84

Athersys Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Athersys Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Athersys Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Athersys's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Athersys (FRA:4LSA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (FRA:4LSA) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

ATHXQ:USA

Address

3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634

Website

https://www.athersys.com

Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.

Athersys (FRA:4LSA) Headlines

No Headlines